Metavallon VC backs gMendel® in €1.2M seed round

Copenhagen-based medtech company gMendel has announced the successful close of a €1.2 million seed funding round led by Metavallon VC. The investment will support the company’s plans to scale its AI-powered genetic screening platform across Latin America, the Middle East, and Africa.

The agreement follows more than a year of evaluation, including due diligence and consultations with international healthcare experts. The process ultimately reinforced confidence in gMendel®’s technology and its potential to address a major global healthcare gap.

Founded in 2020, gMendel® is developing an IVD-certified platform that combines genomics with artificial intelligence to enable faster and more accurate genetic screening. The technology is designed to support early diagnosis in newborns, helping reduce misdiagnosis, improve treatment outcomes, and lower long-term healthcare costs.

Globally, an estimated seven million babies are born each year with genetic disorders, many of which remain undiagnosed, particularly in regions where screening programs are still developing. gMendel® aims to address this gap by enabling healthcare systems to adopt next-generation screening capabilities without the need for extensive legacy infrastructure.

Expanding access to early diagnosis at scale

Recent clinical studies have demonstrated strong performance, with sensitivity reaching up to 98% and specificity up to 100%, supporting the platform’s potential for large-scale deployment.

Dr. Chris Kyriakidis, CEO and co-founder of gMendel®, said the investment represents an important step forward for the company’s mission. “This investment marks a pivotal milestone for gMendel®. It validates not only our technology, but the urgent global need for scalable genetic screening solutions. Together with Metavallon VC, we are accelerating our mission to make early, accurate diagnosis accessible to every newborn, regardless of geography,” he said. “By combining genomics and AI, we have the opportunity to fundamentally change how healthcare systems detect and manage genetic disorders, ultimately saving lives while significantly reducing long-term costs.”

George Karantonis, Partner at Metavallon VC, highlighted the company’s long-term vision and execution capabilities. “We believe gMendel® is uniquely positioned to drive the next generation of genetic screening and improve outcomes at population scale,” he said. “Having followed the team closely, we have been consistently impressed not only by the strength of the technology, but by their commitment to translating innovation into tangible societal impact.”

He also noted that gMendel®’s plans to establish a technology development hub in Greece, along with ongoing discussions with the Greek Ministry of Health regarding potential adoption, further strengthened the firm’s conviction in the investment.

The partnership marks a key milestone in gMendel®’s broader strategy to expand access to early, data-driven screening and reduce infant mortality at scale. By focusing on regions with limited access to advanced diagnostics, the company is positioning itself at the intersection of clinical need and scalable technology deployment.

Metavallon VC, which manages over €70 million in capital and has invested in more than 35 startups since 2018, continues to focus on supporting early-stage companies building across multiple sectors and geographies. This investment was made through its Metavallon II fund, backed by the Hellenic Development Bank of Investments and the European Investment Fund.

As gMendel® moves forward with its expansion plans, the company will look to further validate and deploy its platform in healthcare systems where early genetic screening has the potential to make a measurable difference in patient outcomes.

Source

Metavallon VC

For investors ready to put capital to work

The pace of innovation in healthcare isn’t slowing, and neither are the opportunities to back what comes next. Investor Pass applications are still open for MedTech World North America, taking place from May 11 to 13 in West Palm Beach. The event brings together a strong pipeline of startups, scale-ups, and industry leaders, offering investors the opportunity to source deals, build partnerships, and engage directly with companies shaping the sector.

For those looking to connect more closely with peers, the exclusive Investor Only Forum, powered by Greenberg Traurig on Day 0, provides a dedicated space to engage with fellow investors, exchange perspectives, and explore collaboration opportunities.

For more details, please get in touch with the team at [email protected].